Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Q4 2021 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Q4 2021 earnings summary

9 Nov, 2026

Executive summary

  • 2021 net loss was £102.3m, narrowing from £113.1m in 2020; operating loss was £116.1m vs £128.8m. Cash and cash equivalents were £229.7m at year-end.

  • Operations remained development-stage, with no product sales; 2021 license revenue was £1.1m, primarily from the Moderna agreement.

Financial highlights

  • License revenue rose to £1.079m from £0.187m; R&D expense declined to £96.105m from £103.634m and G&A to £23.545m from £27.576m.

  • Other operating income increased to £4.735m from £2.176m, including £2.629m of lease-termination gains and £1.466m in termination fees.

  • Income tax benefit was £16.171m vs £19.139m; net loss was £102.255m vs £113.092m.

  • Net cash used in operating activities was £83.784m; financing activities provided £206.520m, lifting year-end cash and cash equivalents to £229.702m from £112.177m.

Outlook and guidance

  • Cash of £229.7m was forecast to fund operations through at least 31 May 2023; downside cases included clinical delays, inflation, and missed milestone and R&D tax-credit receipts.

  • Significant R&D, clinical, regulatory, manufacturing and potential commercialization spending is expected; additional funding will be required before meaningful product-sales revenue, if achieved.

  • Profitability depends on successful development, regulatory approval and commercialization of product candidates, and revenue sufficient to support the cost base.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics